248 related articles for article (PubMed ID: 26054597)
1. Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.
Mussai F; Egan S; Hunter S; Webber H; Fisher J; Wheat R; McConville C; Sbirkov Y; Wheeler K; Bendle G; Petrie K; Anderson J; Chesler L; De Santo C
Cancer Res; 2015 Aug; 75(15):3043-53. PubMed ID: 26054597
[TBL] [Abstract][Full Text] [Related]
2. Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.
Fultang L; Gamble LD; Gneo L; Berry AM; Egan SA; De Bie F; Yogev O; Eden GL; Booth S; Brownhill S; Vardon A; McConville CM; Cheng PN; Norris MD; Etchevers HC; Murray J; Ziegler DS; Chesler L; Schmidt R; Burchill SA; Haber M; De Santo C; Mussai F
Cancer Res; 2019 Feb; 79(3):611-624. PubMed ID: 30545920
[TBL] [Abstract][Full Text] [Related]
3. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
4. Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.
Mussai F; Wheat R; Sarrou E; Booth S; Stavrou V; Fultang L; Perry T; Kearns P; Cheng P; Keeshan K; Craddock C; De Santo C
Int J Cancer; 2019 Oct; 145(8):2201-2208. PubMed ID: 30485425
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.
Mussai F; De Santo C; Abu-Dayyeh I; Booth S; Quek L; McEwen-Smith RM; Qureshi A; Dazzi F; Vyas P; Cerundolo V
Blood; 2013 Aug; 122(5):749-58. PubMed ID: 23733335
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
7. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
9. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
Rodriguez PC; Quiceno DG; Zabaleta J; Ortiz B; Zea AH; Piazuelo MB; Delgado A; Correa P; Brayer J; Sotomayor EM; Antonia S; Ochoa JB; Ochoa AC
Cancer Res; 2004 Aug; 64(16):5839-49. PubMed ID: 15313928
[TBL] [Abstract][Full Text] [Related]
10. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
11. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
[No Abstract] [Full Text] [Related]
12. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
14. Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation.
Bian Z; Abdelaal AM; Shi L; Liang H; Xiong L; Kidder K; Venkataramani M; Culpepper C; Zen K; Liu Y
Eur J Immunol; 2018 Jun; 48(6):1046-1058. PubMed ID: 29488625
[TBL] [Abstract][Full Text] [Related]
15. Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.
Camisaschi C; Renne SL; Beretta V; Rini F; Spagnuolo RD; Tuccitto A; Podda MG; Parmiani G; Rivoltini L; Collini P; Castelli C; Luksch R
BMC Cancer; 2018 Oct; 18(1):983. PubMed ID: 30326856
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
17. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
18. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
19. Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression.
Matos A; Carvalho M; Bicho M; Ribeiro R
Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960055
[TBL] [Abstract][Full Text] [Related]
20. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.
Bianchi G; Vuerich M; Pellegatti P; Marimpietri D; Emionite L; Marigo I; Bronte V; Di Virgilio F; Pistoia V; Raffaghello L
Cell Death Dis; 2014 Mar; 5(3):e1135. PubMed ID: 24651438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]